Academic Journal
Dual Inhibition of SRC Family Kinases and Sorafenib Enhances Anti-Tumor Activity in Hepatocellular Carcinoma Cells.
| Τίτλος: | Dual Inhibition of SRC Family Kinases and Sorafenib Enhances Anti-Tumor Activity in Hepatocellular Carcinoma Cells. |
|---|---|
| Συγγραφείς: | Cabral LK; Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park, Campus Basovizza, 34149 Trieste, Italy.; Philippine Council for Health Research and Development, Department of Science and Technology, Saliksik Building, Science Community Complex General Santos Ave., Bicutan, Taguig City 1631, Philippines., Disoma C; Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park, Campus Basovizza, 34149 Trieste, Italy.; Doctoral School of Molecular Biomedicine, Department of Life Sciences, University of Trieste, 34149 Trieste, Italy., Tarchi P; General Surgery Department, Azienda Sanitaria Universitaria Giuliano Isontina, 34128 Trieste, Italy., El-Khobar KE; Eijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia (BRIN), Jakarta Pusat 10340, Indonesia., Agustiningsih A; Eijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia (BRIN), Jakarta Pusat 10340, Indonesia., Dituri F; Personalized Medicine Laboratory, National Institute of Gastroenterology 'S. De Bellis' IRCCS Research Hospital, Via Turi 27, 70013 Bari, Italy., Tiribelli C; Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park, Campus Basovizza, 34149 Trieste, Italy., Sukowati C; Liver Cancer Unit, Fondazione Italiana Fegato ONLUS, AREA Science Park, Campus Basovizza, 34149 Trieste, Italy.; Eijkman Research Center for Molecular Biology, Research Organization for Health, National Research and Innovation Agency of Indonesia (BRIN), Jakarta Pusat 10340, Indonesia. |
| Πηγή: | International journal of molecular sciences [Int J Mol Sci] 2025 Jul 06; Vol. 26 (13). Date of Electronic Publication: 2025 Jul 06. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, [2000- |
| Ιατρικοί όροι (MeSH): | Sorafenib*/pharmacology , Carcinoma, Hepatocellular*/drug therapy , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/metabolism , Carcinoma, Hepatocellular*/genetics , Liver Neoplasms*/drug therapy , Liver Neoplasms*/pathology , Liver Neoplasms*/metabolism , Liver Neoplasms*/genetics , src-Family Kinases*/antagonists & inhibitors , src-Family Kinases*/metabolism , src-Family Kinases*/genetics , Protein Kinase Inhibitors*/pharmacology , Antineoplastic Agents*/pharmacology, Cell Movement/drug effects ; Dasatinib/pharmacology ; Benzodioxoles/pharmacology ; Gene Expression Regulation, Neoplastic/drug effects ; Cell Proliferation/drug effects ; Proto-Oncogene Proteins c-yes/metabolism ; Proto-Oncogene Proteins c-yes/genetics ; Quinolones/pharmacology ; Cell Survival/drug effects ; Humans ; Cell Line, Tumor ; Quinazolines |
| Περίληψη: | Hepatocellular carcinoma (HCC) remains a major clinical challenge due to its high recurrence rate and limited response to monotherapies, such as sorafenib-the standard first-line therapy for advanced HCC. This is partly attributed to its cellular heterogeneity. Increasing evidence implies SRC family kinase (SFK) activation in HCC progression, highlighting the potential of SRC-targeted therapies. In this study, we observed that SRC and YES1 were significantly upregulated in clinical HCC specimens compared to its adjacent non-tumoral tissues (p < 0.001), suggesting relevance as therapeutic targets. High SRC expression was noticed in patients with poor prognosis, as confirmed in TCGA cohort. To evaluate the efficacy of dual targeting, we assessed the combination between SRC inhibitors, saracatinib and dasatinib, with sorafenib in six hepatic cell models, representing both S1 and S2 subtypes. Cytotoxicity assays demonstrated reduced cell viability with the combination therapies compared to either monotherapy, irrespective of the HCC subtype. Wound healing and Transwell migration assays revealed inhibition of cell migration and invasion following combination treatment, underscoring its potential to suppress metastatic behavior. RT-qPCR analysis further confirmed downregulation of the expression of MMP2 and MMP9, genes associated with HCC cell invasion. Additionally, combined therapies decreased VEGFA and HIF1A expression compared to sorafenib alone, suggesting a potential to counteract the adaptive resistance mechanisms of cells to sorafenib. In summary, the combination of SFK inhibitors with sorafenib significantly enhances anti-tumor activity, offering a promising strategy to address HCC cellular heterogeneity and improve treatment efficacy. |
| References: | Clin Chem. 2009 Apr;55(4):611-22. (PMID: 19246619) Annu Rev Cell Dev Biol. 1997;13:513-609. (PMID: 9442882) Dis Model Mech. 2024 Jul 1;17(7):. (PMID: 39051113) J Pharmacol Exp Ther. 2017 Dec;363(3):428-443. (PMID: 29021381) Gan. 1975 Aug;66(4):385-92. (PMID: 52570) Nucleic Acids Res. 2023 Jan 6;51(D1):D638-D646. (PMID: 36370105) Oncologist. 2011;16(5):566-78. (PMID: 21521831) Science. 2017 Aug 18;357(6352):. (PMID: 28818916) Mol Cell. 1999 Dec;4(6):915-24. (PMID: 10635317) Molecules. 2020 Nov 13;25(22):. (PMID: 33202899) Cancers (Basel). 2020 Jun 02;12(6):. (PMID: 32498343) Nat Rev Clin Oncol. 2009 Oct;6(10):587-95. (PMID: 19787002) Int J Mol Sci. 2024 Apr 22;25(8):. (PMID: 38674150) Cancer Cell Int. 2025 Mar 13;25(1):91. (PMID: 40082884) N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514) Mol Clin Oncol. 2020 Oct;13(4):21. (PMID: 32765869) Nat Rev Mol Cell Biol. 2005 Jan;6(1):56-68. (PMID: 15688067) J Med Chem. 2006 Nov 2;49(22):6465-88. (PMID: 17064066) Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102. (PMID: 28407145) CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751) Chin Med J (Engl). 2024 Oct 5;137(19):2334-2342. (PMID: 39227359) Life Sci. 2021 Jan 1;264:118711. (PMID: 33186566) Cell Cycle. 2004 Aug;3(8):1035-42. (PMID: 15254418) Adv Exp Med Biol. 2019;1139:59-81. (PMID: 31134495) Front Biosci (Landmark Ed). 2023 May 11;28(5):90. (PMID: 37258470) Hepatology. 2007 Jan;45(1):42-52. (PMID: 17187432) Cancer Res. 2006 Jun 1;66(11):5790-7. (PMID: 16740718) Gastroenterology. 2019 Sep;157(3):760-776. (PMID: 31063779) Cell. 2017 Jun 15;169(7):1327-1341.e23. (PMID: 28622513) World J Gastroenterol. 2006 Sep 21;12(35):5743-5. (PMID: 17007035) Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198. (PMID: 31066453) Oncol Lett. 2023 Oct 25;26(6):529. (PMID: 38020292) Nat Rev Cancer. 2009 Nov;9(11):798-809. (PMID: 19851315) Clin Lung Cancer. 2014 Jan;15(1):52-7. (PMID: 24169259) Biochem J. 2001 Nov 15;360(Pt 1):255-64. (PMID: 11696015) Clin Ther. 2007 Nov;29(11):2289-308. (PMID: 18158072) Nat Genet. 2013 Oct;45(10):1113-20. (PMID: 24071849) Cancers (Basel). 2020 Jun 15;12(6):. (PMID: 32549224) Pharmacol Rev. 2006 Sep;58(3):621-81. (PMID: 16968952) Dig Liver Dis. 2024 May;56(5):872-879. (PMID: 37783655) Semin Liver Dis. 2005;25(2):125-32. (PMID: 15918141) J Clin Oncol. 2013 Apr 20;31(12):1592-605. (PMID: 23509311) Pharmacol Res. 2015 Apr;94:9-25. (PMID: 25662515) Oncogene. 2022 Nov;41(45):4917-4928. (PMID: 36217026) Science. 2015 May 8;348(6235):648-60. (PMID: 25954001) J Med Chem. 2004 Dec 30;47(27):6658-61. (PMID: 15615512) Nat Rev Dis Primers. 2021 Jan 21;7(1):6. (PMID: 33479224) Anticancer Drugs. 2009 Mar;20(3):179-84. (PMID: 19396016) Mol Cancer Ther. 2010 Mar;9(3):742-50. (PMID: 20197401) Biomedicines. 2023 Jan 25;11(2):. (PMID: 36830879) Hepatology. 1996 Aug;24(2):316-22. (PMID: 8690399) |
| Contributed Indexing: | Keywords: SRC family kinases; cellular heterogeneity; hepatocellular carcinoma; sorafenib |
| Substance Nomenclature: | 9ZOQ3TZI87 (Sorafenib) EC 2.7.10.2 (src-Family Kinases) RBZ1571X5H (Dasatinib) 9KD24QGH76 (saracatinib) 0 (Protein Kinase Inhibitors) 0 (Benzodioxoles) 0 (Antineoplastic Agents) EC 2.7.10.2 (Proto-Oncogene Proteins c-yes) 0 (Quinolones) 0 (Quinazolines) |
| Entry Date(s): | Date Created: 20250712 Date Completed: 20250712 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12250370 |
| DOI: | 10.3390/ijms26136506 |
| PMID: | 40650282 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1422-0067 |
|---|---|
| DOI: | 10.3390/ijms26136506 |